William Blair Comments on Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Krystal Biotech in a research note issued to investors on Wednesday, February 19th. William Blair analyst S. Corwin expects that the company will post earnings per share of $1.91 for the quarter. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2026 earnings at $2.36 EPS, Q3 2026 earnings at $2.63 EPS and Q4 2026 earnings at $3.07 EPS.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.30 earnings per share.

A number of other research analysts have also recently weighed in on KRYS. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Stock Up 3.7 %

Shares of NASDAQ KRYS opened at $182.62 on Friday. The stock has a market capitalization of $5.25 billion, a PE ratio of 61.08 and a beta of 0.84. The firm has a fifty day moving average of $157.37 and a 200-day moving average of $175.23. Krystal Biotech has a 52-week low of $107.50 and a 52-week high of $219.34.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter valued at $40,000. Values First Advisors Inc. purchased a new position in Krystal Biotech in the 3rd quarter valued at about $53,000. Huntington National Bank grew its stake in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the fourth quarter worth about $95,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).